Clinical Trials Logo

Short Bowel Syndrome clinical trials

View clinical trials related to Short Bowel Syndrome.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06427642 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.

NCT ID: NCT06185088 Recruiting - Clinical trials for Short Bowel Syndrome

MENDD Tolerance Assessment Study

Start date: March 6, 2023
Phase: N/A
Study type: Interventional

This study will utilize approved devices in an off-label manner to create forces required to induce intestinal lengthening. Radial and longitudinal forces are both required, and two devices will be used to create forces in order to test tolerability of said forces. This is to provide evidence that humans could tolerate the forces produced by a proposed commercially built device. This study will test the hypothesis that radial and longitudinal forces necessary to produce enterogenesis will cause low levels of discomfort in healthy adults. Approved devices will be utilized in an off-label manner to reproduce forces similar to our novel medical device which is designed to treat short bowel syndrome (SBS). This trial will not be testing a treatment for SBS, and individuals with SBS are ineligible for recruitment.

NCT ID: NCT05561647 Recruiting - Clinical trials for Short Bowel Syndrome (SBS)

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX

GATTEX KAB
Start date: August 1, 2013
Phase:
Study type: Observational

The main aim of this study is to document the level of knowledge and assess attitudes and behaviors of both participants and physicians regarding the risks and safe use of GATTEX. The survey will be done via internet, telephone, or paper and patients will be able to choose the method that is preferred. No study medicines will be provided to patients in this study.

NCT ID: NCT05535361 Recruiting - Clinical trials for Short Bowel Syndrome

A Feasibility Study to Evaluate Safety & Benefit of Eclipse XL1 System in Adult Patients With SBS

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System in Adult Patients with Short Bowel Syndrome shall enroll up to 5 Subjects at up to 2 study sites in the United States.

NCT ID: NCT05432648 Recruiting - Short Gut Syndrome Clinical Trials

Fiber Food Introduction in Pediatric Short Bowel Syndrome

Start date: May 8, 2022
Phase: N/A
Study type: Interventional

Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.

NCT ID: NCT05371028 Recruiting - Clinical trials for Short Bowel Syndrome (SBS)

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Start date: September 23, 2023
Phase:
Study type: Observational

The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada. This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study. The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.

NCT ID: NCT05302531 Recruiting - Clinical trials for Short Bowel Syndrome

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

GRAAL
Start date: December 9, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.

NCT ID: NCT05023382 Recruiting - Clinical trials for Short Bowel Syndrome

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Start date: September 1, 2021
Phase:
Study type: Observational

The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.

NCT ID: NCT04775706 Recruiting - Clinical trials for Short Bowel Syndrome

Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Start date: March 3, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with SBS-associated intestinal failure (SBS-IF).

NCT ID: NCT04733066 Recruiting - Clinical trials for Short Bowel Syndrome

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

MatchedQoL
Start date: September 1, 2020
Phase:
Study type: Observational

The aim of this prospective longitudinal study is to compare the quality of life of short bowel patients prior to and on teduglutide treatment with a non-treated patient group in a matched-pair design.